Premium
Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long‐term survivors of aggressive adult T‐cell leukaemia‐lymphoma (JCOG0902A)
Author(s) -
Fukushima Takuya,
Nomura Shogo,
Shimoyama Masanori,
Shibata Taro,
Imaizumi Yoshitaka,
Moriuchi Yoshiyuki,
Tomoyose Takeaki,
Uozumi Kimiharu,
Kobayashi Yukio,
Fukushima Noriyasu,
Utsunomiya Atae,
Tara Mitsutoshi,
Nosaka Kisato,
Hidaka Michihiro,
Uike Naokuni,
Yoshida Shinichiro,
Tamura Kazuo,
Ishitsuka Kenji,
Kurosawa Mitsutoshi,
Nakata Masanobu,
Fukuda Haruhiko,
Hotta Tomomitsu,
Tobinai Kensei,
Tsukasaki Kunihiro
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12962
Subject(s) - medicine , hazard ratio , proportional hazards model , oncology , lymphoma , multivariate analysis , cohort , clinical trial , international prognostic index , confidence interval , diffuse large b cell lymphoma
Summary This study evaluated the clinical features of 276 patients with aggressive adult T‐cell leukaemia‐lymphoma (ATL) in 3 Japan Clinical Oncology Group (JCOG) trials. We assessed the long‐term survivors who survived >5 years and constructed a prognostic index (PI), named the JCOG‐PI, based on covariates obtained by Cox regression analysis. The median survival time (MST) of the entire cohort was 11 months. In 37 patients who survived >5 years, no disease‐related deaths in 10 patients with lymphoma‐type were observed in contrast to the 10 ATL‐related deaths in other types. In multivariate analysis of 193 patients, the JCOG‐PI based on corrected calcium levels and performance status identified moderate and high risk groups with an MST of 14 and 8 months respectively (hazard ratio, 1·926). The JCOG‐PI was reproducible in an external validation. Patients with lymphoma‐type who survived >5 years might have been cured. The JCOG‐PI is valuable for identifying patients with extremely poor prognosis and will be useful for the design of future trials combining new drugs or investigational treatment strategies.